Immunic, Inc.
IMUX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $100 | $66 | $45 | $226 |
| - Cash | $36 | $47 | $107 | $87 |
| + Debt | $1 | $1 | $2 | $1 |
| Enterprise Value | $66 | $21 | -$61 | $140 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$98 | -$99 | -$86 | -$92 |
| % Margin | – | – | – | – |
| Net Income | -$101 | -$94 | -$120 | -$93 |
| % Margin | – | – | – | – |
| EPS Diluted | -1 | -2.11 | -3.78 | -3.92 |
| % Growth | 52.6% | 44.2% | 3.6% | – |
| Operating Cash Flow | -$85 | -$71 | -$65 | -$83 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$85 | -$71 | -$65 | -$83 |